ABILIFY- aripiprazole tablet
ABILIFY- aripiprazole solution
ABILIFY- aripiprazole tablet, orally disintegrating
ABILIFY- arip США - англійська - NLM (National Library of Medicine)

abilify- aripiprazole tablet abilify- aripiprazole solution abilify- aripiprazole tablet, orally disintegrating abilify- arip

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

ABILIFY MAINTENA POWDER AND SOLVENT FOR PROLONGED RELEASE SUSPENSION FOR INJECTION 400 MG Сінгапур - англійська - HSA (Health Sciences Authority)

abilify maintena powder and solvent for prolonged release suspension for injection 400 mg

lundbeck singapore pte. ltd. - sterile aripiprazole monohydrate 416mg/vial equivalent to anhydrous aripiprazole - injection, powder, for suspension, extended release - sterile aripiprazole monohydrate 416mg/vial equivalent to anhydrous aripiprazole 400mg/vial

Tna-Peri See formulation on CPR Solution For Iv Infusion Філіппіни - англійська - FDA (Food And Drug Administration)

tna-peri see formulation on cpr solution for iv infusion

otsuka (phils.) pharmaceutical, inc.; distributor: macropharma corporation - glucose 15% (w/v) solution for iv infusion; amino acids 10% (wlv) '\.vtth electrolytes solution for intravenous injection; intravenous fat emulsion with medium and long chain triglycerides 20% emulsion for intravenous infusion - solution for iv infusion - see formulation on cpr

Tna Філіппіни - англійська - FDA (Food And Drug Administration)

tna

otsuka (phils.) pharmaceutical, inc.; distributor: macropharma corporation - glucose 30% (w/v) solution for iv infusion; amino acid 10% (w/v) with electrolytes solution for iv injection; intravenous fat emulsion with medium and long chain triglycerides 20% emulsion for iv infusion - see formulation on reverse side - (see formulation on reverse side)